Komori
Nihon Nohyaku (4997) · PolicyAdvanced

Review of Policy Shareholdings and Consideration of Their Reduction

First written in FY2021. 4 of 5 entries say "Advanced", first in FY2022. Latest entry: FY2026.

5entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2021AdvancedFY2022 – FY20262021: 120212022: 120222023: 120232024: 020242025: 120252026: 12026
Same theme, other companies
Review of the Rationale for Holding Strategic ShareholdingsA theme 1258 companies write about · 1 as a headwind · 666 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 1262 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「Most recently, the company conducted a review in October 2025 and reported the results to the Board of Directors at its meeting held in November of the same year. The company promptly sells cross-shareholdings that clearly no longer align with its holding policy and considers reducing its holdings in stages based on the review results and other factors.」

    The company conducted a review of its cross-shareholdings in October 2025 and continued implementing its policy of reducing holdings, including the reduction or sale of 1 unlisted holding and 1 listed holding.
  2. FY2025AdvancedAnnual report

    「Most recently, the company conducted a review in October 2024 and reported the results to the Board of Directors at its meeting held in November of the same year. The company promptly sells cross-shareholdings that clearly no longer align with its holding policy and considers reducing its holdings in stages based on the review results and other factors.」

    The company conducted a review of its cross-shareholdings in October 2024 and continued implementing its reduction policy, including the sale of 1 unlisted holding and recognition of ¥153 million in sale proceeds.
  3. FY2023AdvancedAnnual report

    「Most recently, the company conducted a review in October 2022 and reported the results to the Board of Directors at its meeting held in November of the same year. The company promptly sells cross-shareholdings that clearly no longer align with its holding policy and considers reducing its holdings in stages based on the review results and other factors.」

    The company conducted a review of its cross-shareholdings in October 2022 and sold 2 holdings other than unlisted shares, recognizing ¥22 million in sale proceeds.
  4. FY2022AdvancedAnnual report

    「Most recently, the company conducted a review in October 2021 and reported the results to the Board of Directors at its meeting held in November of the same year. The company promptly sells cross-shareholdings that clearly no longer align with its holding policy and considers reducing its holdings in stages based on the review results and other factors.」

    The company conducted a review of its cross-shareholdings in October 2021 and described the implementation of its reduction policy, including the sale of 5 holdings other than unlisted shares and recognition of ¥95 million in sale proceeds.
  5. FY2021First statedAnnual report

    「The company reviews its listed shares and other holdings, hereinafter referred to as "cross-shareholdings," in terms of their medium- to long-term economic rationale and the benefits of holding them from the perspective of maintaining and strengthening overall relationships with business partners, and reports the results to the Board of Directors. Most recently, the company conducted a review in November 2020 and reported the results to the Board of Directors at its meeting held in December of the same year. The company promptly sells cross-shareholdings that clearly no longer align with its holding policy and considers reducing its holdings in stages based on the review results and other factors.」

    The company has stated a policy of reviewing the economic rationale and benefits of holding cross-shareholdings, promptly selling holdings that do not align with its policy, and considering reductions in its holdings.
Moved together

"Promotion and Sales Expansion of Internally Developed Products and Expansion of Overseas Operations" moved the same way as this thread, in the same document, in 4 of its 5 moves.

444444★123456
  1. ★This thread
  2. 1Promotion and Sales Expansion of Internally Developed Products and Expansion of Overseas Operations4×
  3. 2Improving domestic earnings through sales-company collaboration and a focus on core businesses4×
  4. 3Growth Strategy and the Pursuit of a Highly Profitable Business Structure through AGG20184×
  5. 4Expanding the Product Portfolio Through New Product Launches4×
  6. 5Strengthening Drug Discovery Capabilities and Building a Global R&D Organization4×
  7. 6Expansion of Overseas Bases and Acceleration of Pesticide Registrations in Each Country4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Nihon Nohyaku yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.